Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection.

Shuptrine CW, Ajina R, Fertig EJ, Jablonski SA, Kim Lyerly H, Hartman ZC, Weiner LM.

Cancer Immunol Immunother. 2017 Dec;66(12):1529-1544. doi: 10.1007/s00262-017-2047-2. Epub 2017 Aug 2.

2.

Benzimidazole inhibitors from the Niclosamide chemotype inhibit Wnt/β-catenin signaling with selectivity over effects on ATP homeostasis.

Mook RA Jr, Ren XR, Wang J, Piao H, Barak LS, Kim Lyerly H, Chen W.

Bioorg Med Chem. 2017 Mar 15;25(6):1804-1816. doi: 10.1016/j.bmc.2017.01.046. Epub 2017 Feb 3.

3.

Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone.

Price TT, Burness ML, Sivan A, Warner MJ, Cheng R, Lee CH, Olivere L, Comatas K, Magnani J, Kim Lyerly H, Cheng Q, McCall CM, Sipkins DA.

Sci Transl Med. 2016 May 25;8(340):340ra73. doi: 10.1126/scitranslmed.aad4059.

PMID:
27225183
4.

Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects.

Osada T, Berglund P, Morse MA, Hubby B, Lewis W, Niedzwiecki D, Yang XY, Hobeika A, Burnett B, Devi GR, Clay TM, Smith J, Kim Lyerly H.

Cancer Immunol Immunother. 2012 Nov;61(11):1941-51. doi: 10.1007/s00262-012-1248-y. Epub 2012 Apr 10.

5.

Maximizing the retention of antigen specific lymphocyte function after cryopreservation.

Disis ML, dela Rosa C, Goodell V, Kuan LY, Chang JC, Kuus-Reichel K, Clay TM, Kim Lyerly H, Bhatia S, Ghanekar SA, Maino VC, Maecker HT.

J Immunol Methods. 2006 Jan 20;308(1-2):13-8. Epub 2005 Oct 21.

PMID:
16337957
6.

Current status of dendritic cell immunotherapy of malignancies.

Mosca PJ, Clay TM, Kim Lyerly H, Morse MA.

Int Rev Immunol. 2003 May-Aug;22(3-4):255-81. Review.

PMID:
12745642

Supplemental Content

Loading ...
Support Center